04.09.14
Privately held IlluminOss Medical Inc. has received three new patents for its Photodynamic Bone Stabilization System (PBSS) instruments.
The East Providence, R.I.-based company now holds 32 U.S. and international patents protecting the company’s fracture fixation technology and its application on bones and procedures throughout the body.
The patents issued, “Apparatus and Methods for Repairing Craniomaxillofacial Bones,” “Apparatus for Delivery of Reinforcing Materials to Bone,” and “Photodynamic Bone Stabilization and Drug Delivery Systems,” provide additional protection to the company’s intellectual property (IP) portfolio for the minimally invasive internal fixation of broken bones with PBSS.
“This IP portfolio demonstrates that we are continuing to advance our fracture fixation technologies as we expand our commercial efforts in Europe and work towards gaining regulatory approval in the United States,” said Robert Rabiner, founder and chief technology officer of IlluminOss. “With the addition of these three new patents, we can confidently say that our IP portfolio covers the whole body.”
The minimally invasive PBSS quickly stabilizes bone fractures or prevents impending fractures through a percutaneous, patient customized fracture fixation system that addresses a significant unmet need in pathological and osteoporotic fractures. Using PBBS, clinicians insert an angioplasty-like balloon into the intramedullary canal across the fracture site, which is then filled with a liquid monomer. Once the positioning of the implant is verified using fluoroscopy, light is delivered through a proprietary fiber to cure the monomer for rapid stabilization of the bone. This results in a customized fit to each patient’s specific anatomy providing rotational and torsional stability to the fracture. PBSS can be implanted for stand-alone primary fixation or in combination with screws or plates.
Dirk Kuyper, president and CEO of IlluminOss, said, “IlluminOss is gathering compelling clinical evidence that shows how our patient-customized approach to fracture repair has the potential to improve clinical outcomes.”
IlluminOss Medical is a commercial stage company that designs, develops and markets orthopedic fracture repair products that leverage its bone stabilization technology. The company currently markets its products under CE Mark approval in Austria, Germany, Israel, Italy, the Netherlands, Spain, Switzerland and Turkey. Its products are investigational devices and are not approved for sale in the United States.
Founded in 2007, IlluminOss is funded by Foundation Medical Partners, New Leaf Venture Partners, Tekla Capital, Life Sciences Partners, SR One, Longwood Fund, Excel Venture Management, Pappas Ventures, Mieza Capital and Slater Technology.
The East Providence, R.I.-based company now holds 32 U.S. and international patents protecting the company’s fracture fixation technology and its application on bones and procedures throughout the body.
The patents issued, “Apparatus and Methods for Repairing Craniomaxillofacial Bones,” “Apparatus for Delivery of Reinforcing Materials to Bone,” and “Photodynamic Bone Stabilization and Drug Delivery Systems,” provide additional protection to the company’s intellectual property (IP) portfolio for the minimally invasive internal fixation of broken bones with PBSS.
“This IP portfolio demonstrates that we are continuing to advance our fracture fixation technologies as we expand our commercial efforts in Europe and work towards gaining regulatory approval in the United States,” said Robert Rabiner, founder and chief technology officer of IlluminOss. “With the addition of these three new patents, we can confidently say that our IP portfolio covers the whole body.”
The minimally invasive PBSS quickly stabilizes bone fractures or prevents impending fractures through a percutaneous, patient customized fracture fixation system that addresses a significant unmet need in pathological and osteoporotic fractures. Using PBBS, clinicians insert an angioplasty-like balloon into the intramedullary canal across the fracture site, which is then filled with a liquid monomer. Once the positioning of the implant is verified using fluoroscopy, light is delivered through a proprietary fiber to cure the monomer for rapid stabilization of the bone. This results in a customized fit to each patient’s specific anatomy providing rotational and torsional stability to the fracture. PBSS can be implanted for stand-alone primary fixation or in combination with screws or plates.
Dirk Kuyper, president and CEO of IlluminOss, said, “IlluminOss is gathering compelling clinical evidence that shows how our patient-customized approach to fracture repair has the potential to improve clinical outcomes.”
IlluminOss Medical is a commercial stage company that designs, develops and markets orthopedic fracture repair products that leverage its bone stabilization technology. The company currently markets its products under CE Mark approval in Austria, Germany, Israel, Italy, the Netherlands, Spain, Switzerland and Turkey. Its products are investigational devices and are not approved for sale in the United States.
Founded in 2007, IlluminOss is funded by Foundation Medical Partners, New Leaf Venture Partners, Tekla Capital, Life Sciences Partners, SR One, Longwood Fund, Excel Venture Management, Pappas Ventures, Mieza Capital and Slater Technology.